Bristol-Myers Squibb Company (BMY)
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know
Bristol Myers Squibb (BMY) closed at $48.02 in the latest trading session, marking a +2.85% move from the prior day.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Will Increased Expenses Affect Bristol Myers' Performance?
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends
The Dividend Harvesting Portfolio hit new all-time highs in value, profitability, and forward income, with a 29.58% return on invested capital. Consistent weekly investing, diversification, and a focus on income-producing assets have driven strong performance, even through volatile markets and macroeconomic headwinds. I see significant opportunities ahead, especially for big tech, REITs, and energy stocks, as the Fed's delayed rate cuts create a favorable environment.
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, since only half its revenue affects BMY's bottom line due to the Pfizer partnership. Earnings have been depressed by past acquisition amortizations, but these charges will drop sharply, revealing stronger profitability.
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $47.66, denoting a +1.32% move from the preceding trading day.
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
2 Wonderful Dividends At Bargain Basement Prices
Uncertainty creates value opportunities. In this article, I highlight two value stocks trading far below their historical valuations. Both offer dividend yields that are well above historical average and strong growth potential. Both stocks exemplify how investors can secure decent yields and future upside by buying quality companies when market sentiment is overly pessimistic.
